Article: Merck Cancels Work on a New Insomnia Medication - New York Times

Two weeks after the Food and Drug Administration issued safety warnings about widely used sleeping pills, the drug maker Merck canceled a venture into the shifting market for insomnia medications. Merck and its Danish partner, H. Lundbeck, announced that a safe and effective sleeping pill had eluded their scientists after years of study, and they canceled their joint product, gaboxadol. Unusual side effects - including hallucinations and disorientation - showed up in the studies. The drug also failed a trial of its efficacy.During a conference call yesterday, Lundbeck's senior vice president for drug development, Anders Gersel Pedersen, said, "We did not want to bring a product to the ...

Read all of this article (available on a partner's Web site)

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!